Opel, that's a ridiculous comparison! We're not trying to sell magnetic knee patches! Yep, the SP is in the absolute gutter, and will probably hit 1.5c in the next week....but can everyone just take a backward step and think about where we are? Have a think back to Diasource, or Eugeni. We've actually got products with sound datasets this time around.
Yes, dilution is a huge issue, and raising at these lows really stings. And yes, management could definitely sell the story to pump the SP prior to a CR. That is 100% given. But dilution is dilution...the end game from here is multi-bagging right? This is a painful stage of the game but it's a bit rich to denigrate us to lights-out stage.
Anteobind is in that many bloody research papers these days that there is enough volume of evidence to show there is a business case for it. As was said at the AGM, the revision of the life sciences division saw the need to reduce costs and reformulate to the NXT product. This was done to reduce costs, which by all accounts of Anteobind, was the major aspect holding it back from broad adoption across the diagnostics industry. This has legs and it very well could run. Especially the SIOI & Vidcare contracts. India is a behemoth.
As for CET, well, we've just got a decent dataset update. 1000mAh/g is amazing. I'd love to see 1000 cycles at 80%, and to managements credit, that is the primary focus. If that anode density is replicable at mass-scale, then it'll truly be a part of a step change in the energy transition. No joke, at that density you're talking about electric aircraft. Such a huge market that regardless of where our SP is at the moment (yes, friggin horrible), we'll be doing well if we can get even a small chunk of it.
ADO Price at posting:
1.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)